Neurologic Manifestations of Chronic Methamphetamine Abuse

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Neurologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Streatfeild D.
        Cocaine: an unauthorized biography.
        Picador, New York2001
        • Nagai T.
        • Kamiyama S.
        Forensic toxicologic analysis of methamphetamine and amphetamine optical isomers by high performance liquid chromatography.
        Int J Legal Med. 1988; 101: 151-159
        • Nagai H.
        Studies on the components of Ephedraceae in herb medicine.
        Yahugaku Zasshi. 1893; 139: 901-933
        • Miller M.A.
        History and epidemiology of amphetamine abuse in the United States.
        in: Klee H. Amphetamine misuse: international perspectives on current trends. Harwood Academic Publishers, Reading (UK)1997: 113-133
        • Anglin M.D.
        • Burke C.
        • Perrochet B.
        • et al.
        History of the methamphetamine problem.
        J Psychoactive Drugs. 2000; 32: 137-141
        • Wilson J.M.
        • Kalasinsky K.S.
        • Levey A.I.
        • et al.
        Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.
        Nat Med. 1996; 2: 699-703
        • Suwaki H.
        • Fukui S.
        • Konuma K.
        Methamphetamine abuse in Japan: its 45 year history and the current situation.
        in: Klee H. Amphetamine misuse: international perspectives on current trends. Harwood Academic Publishers, Reading (UK)1997
        • Hunt D.
        • Kuck S.
        • Truitt L.
        Methamphetamine use: lessons learned: report to the National Institute of Justice.
        Abt Associates Inc, Cambridge (MA)2006 (Available at:) (Accessed May 10, 2011)
        • UNDOC
        Annual Report 2008.
        (Available at:) (Accessed January 19, 2011)
        • Gonzales R.
        • Mooney L.
        • Rawson R.A.
        The Methamphetamine Problem in the United States.
        Annu Rev Public Health. 2010; 31: 385-398
      1. Office of National Drug Control Policy. II. America’s Drug Use Profile.
        (Available at:)
        http://www.ncjrs.gov/ondcppubs/publications/policy/ndcs01/chap2.html
        (Accessed January 19, 2011)
        • Derlet R.W.
        • Heischober B.
        Methamphetamine. Stimulant of the 1990s?.
        West J Med. 1990; 153: 625-628
      2. Costs of Meth. Available at: http://www5.semo.edu/criminal/medfels/text_meth_cost.htm. Accessed January 19, 2011.

        • Denehy J.
        The meth epidemic: its effect on children and communities.
        J Sch Nurs. 2006; 22: 63-65
        • Betsinger G.
        Coping with meth lab hazards.
        Occup Health Saf. 2006; 75 (52, 54–8, passim): 50
        • Cruickshank C.C.
        • Dyer K.R.
        A review of the clinical pharmacology of methamphetamine.
        Addiction. 2009; 104: 1085-1099
        • Lake C.R.
        • Quirk R.S.
        CNS stimulants and look-alike drugs.
        Psychiatr Clin North Am. 1984; 7: 689-701
        • Brandle E.
        • Fritzsch G.
        • Greven J.
        Affinity of different local anesthetic drugs and catecholamines for the contraluminal transport system for organic cations in proximal tubules of rat kidneys.
        J Pharmacol Exp Ther. 1992; 260: 734-741
        • Fleckenstein A.E.
        • Volz T.J.
        • Riddle E.L.
        • et al.
        New insights into the mechanism of action of amphetamines.
        Annu Rev Pharmacol Toxicol. 2007; 47: 681-698
        • Schep L.J.
        • Slaughter R.J.
        • Beasley D.M.
        The clinical toxicology of metamfetamine.
        Clin Toxicol (Phila). 2010; 48: 675-694
        • Suzuki O.
        • Hattori H.
        • Asano M.
        • et al.
        Inhibition of monoamine oxidase by d-methamphetamine.
        Biochem Pharmacol. 1980; 29: 2071-2073
        • Meredith C.W.
        • Jaffe C.
        • Ang-Lee K.
        • et al.
        Implications of chronic methamphetamine use: a literature review.
        Harv Rev Psychiatry. 2005; 13: 141-154
        • O’Connor A.D.
        • Rusyniak D.E.
        • Bruno A.
        Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse.
        Med Clin North Am. 2005; 89: 1343-1358
        • Rusyniak D.E.
        • Sprague J.E.
        Hyperthermic syndromes induced by toxins.
        Clin Lab Med. 2006; 26: 165-184
        • Yamamoto B.K.
        • Moszczynska A.
        • Gudelsky G.A.
        Amphetamine toxicities.
        Ann N Y Acad Sci. 2010; 1187: 101-121
        • Rippeth J.D.
        • Heaton R.K.
        • Carey C.L.
        • et al.
        Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons.
        J Int Neuropsychol Soc. 2004; 10: 1-14
        • Scott J.C.
        • Woods S.P.
        • Matt G.E.
        • et al.
        Neurocognitive effects of methamphetamine: a critical review and meta-analysis.
        Neuropsychol Rev. 2007; 17: 275-297
        • Tulving E.
        Episodic memory: from mind to brain.
        Annu Rev Psychol. 2002; 53: 1-25
        • Hoffman W.F.
        • Schwartz D.L.
        • Huckans M.S.
        • et al.
        Cortical activation during delay discounting in abstinent methamphetamine dependent individuals.
        Psychopharmacology (Berl). 2008; 201: 183-193
        • Gilbert S.J.
        • Burgess P.W.
        Executive function.
        Curr Biol. 2008; 18: R110-R114
        • Caligiuri M.P.
        • Buitenhuys C.
        Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?.
        Neuropsychopharmacology. 2005; 30: 2125-2134
        • Moszczynska A.
        • Fitzmaurice P.
        • Ang L.
        • et al.
        Why is parkinsonism not a feature of human methamphetamine users?.
        Brain. 2004; 127: 363-370
        • Glasner-Edwards S.
        • Mooney L.J.
        • Marinelli-Casey P.
        • et al.
        Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning.
        Am J Addict. 2010; 19: 385-390
        • Hall W.
        • Hando J.
        • Darke S.
        • et al.
        Psychological morbidity and route of administration among amphetamine users in Sydney, Australia.
        Addiction. 1996; 91: 81-87
        • McKetin R.
        • Ross J.
        • Kelly E.
        • et al.
        Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants.
        Drug Alcohol Rev. 2008; 27: 277-285
        • Copeland A.L.
        • Sorensen J.L.
        Differences between methamphetamine users and cocaine users in treatment.
        Drug Alcohol Depend. 2001; 62: 91-95
        • Newton T.F.
        • Kalechstein A.D.
        • Duran S.
        • et al.
        Methamphetamine abstinence syndrome: preliminary findings.
        Am J Addict. 2004; 13: 248-255
        • Nordahl T.E.
        • Salo R.
        • Leamon M.
        Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review.
        J Neuropsychiatry Clin Neurosci. 2003; 15: 317-335
        • Iwanami A.
        • Sugiyama A.
        • Kuroki N.
        • et al.
        Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report.
        Acta Psychiatr Scand. 1994; 89: 428-432
        • Sato M.
        A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis.
        Ann N Y Acad Sci. 1992; 654: 160-170
        • Shimazono Y.
        • Matsushima E.
        Behavioral and neuroimaging studies on schizophrenia in Japan.
        Psychiatry Clin Neurosci. 1995; 49: 3-11
        • Yui K.
        • Ikemoto S.
        • Ishiguro T.
        • et al.
        Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia.
        Ann N Y Acad Sci. 2000; 914: 1-12
        • Hawks D.
        • Mitcheson M.
        • Ogborne A.
        • et al.
        Abuse of methylamphetamine.
        Br Med J. 1969; 2: 715-721
        • Srisurapanont M.
        • Ali R.
        • Marsden J.
        • et al.
        Psychotic symptoms in methamphetamine psychotic in-patients.
        Int J Neuropsychopharmacol. 2003; 6: 347-352
        • Mahoney 3rd, J.J.
        • Kalechstein A.D.
        • De La Garza 2nd, R.
        • et al.
        Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants.
        Am J Addict. 2008; 17: 83-98
        • Ellinwood E.H.
        Amphetamine Psychosis: I. Description of the individuals and process.
        J Nerv Ment Dis. 1967; 144: 273-283
        • Angrist B.
        • Lee H.K.
        • Gershon S.
        The antagonism of amphetamine-induced symptomatology by a neuroleptic.
        Am J Psychiatry. 1974; 131: 817-819
        • Snyder S.H.
        Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.
        Am J Psychiatry. 1973; 130: 61-67
        • Chen C.K.
        • Lin S.K.
        • Sham P.C.
        • et al.
        Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis.
        Psychol Med. 2003; 33: 1407-1414
        • Chen C.K.
        • Lin S.K.
        • Sham P.C.
        • et al.
        Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis.
        Am J Med Genet. 2005; 136B: 87-91
        • Bell D.S.
        The experimental reproduction of amphetamine psychosis.
        Arch Gen Psychiatry. 1973; 29: 35-40
        • Lieberman J.A.
        • Kinon B.J.
        • Loebel A.D.
        Dopaminergic mechanisms in idiopathic and drug-induced psychoses.
        Schizophr Bull. 1990; 16: 97-110
        • Bell D.S.
        Comparison of amphetamine psychosis and schizophrenia.
        Br J Psychiatry. 1965; 111: 701-707
        • Buckley P.F.
        Substance abuse in schizophrenia: a review.
        J Clin Psychiatry. 1998; 59: 26-30
        • Chambers R.A.
        • Krystal J.H.
        • Self D.W.
        A neurobiological basis for substance abuse comorbidity in schizophrenia.
        Biol Psychiatry. 2001; 50: 71-83
        • Richards J.R.
        • Bretz S.W.
        • Johnson E.B.
        • et al.
        Methamphetamine abuse and emergency department utilization.
        West J Med. 1999; 170: 198-202
        • de Leon J.
        • Antelo R.E.
        • Simpson G.
        Delusion of parasitosis or chronic tactile hallucinosis: hypothesis about their brain physiopathology.
        Compr Psychiatry. 1992; 33: 25-33
        • Ellinwood E.H.
        • Sudilovsky A.
        Chronic amphetamine intoxication: behavioral model of psychoses.
        in: Cole J.O. Freedman A.M. Friedhoff A.J. Psychopathology and psychopharmacology. Johns Hopkins University Press, Baltimore (MD)1972: 51-70
        • Yaffee H.S.
        Cutaneous stigmas associated with Methedrine (methamphetamine).
        Arch Dermatol. 1971; 104: 687
        • Ellison G.D.
        • Eison M.S.
        Continuous amphetamine intoxication: an animal model of the acute psychotic episode.
        Psychol Med. 1983; 13: 751-761
        • Liu S.W.
        • Lien M.H.
        • Fenske N.A.
        The effects of alcohol and drug abuse on the skin.
        Clin Dermatol. 2010; 28: 391-399
        • Cohen A.L.
        • Shuler C.
        • McAllister S.
        • et al.
        Methamphetamine use and methicillin-resistant Staphylococcus aureus skin infections.
        Emerg Infect Dis. 2007; 13: 1707-1713
        • Siegel R.K.
        Cocaine hallucinations.
        Am J Psychiatry. 1978; 135: 309-314
        • Rylander G.
        Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs.
        Psychiatr Neurol Neurochir. 1972; 75: 203-212
        • Schiorring E.
        Psychopathology induced by "speed drugs".
        Pharmacol Biochem Behav. 1981; 14: 109-122
        • Fasano A.
        • Petrovic I.
        Insights into pathophysiology of punding reveal possible treatment strategies.
        Mol Psychiatry. 2010; 15: 560-573
        • O’Sullivan S.S.
        • Evans A.H.
        • Lees A.J.
        Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
        CNS Drugs. 2009; 23: 157-170
        • Lundh H.
        • Tunving K.
        An extrapyramidal choreiform syndrome caused by amphetamine addiction.
        J Neurol Neurosurg Psychiatry. 1981; 44: 728-730
        • Rhee K.J.
        • Albertson T.E.
        • Douglas J.C.
        Choreoathetoid disorder associated with amphetamine-like drugs.
        Am J Emerg Med. 1988; 6: 131-133
        • Randrup A.
        • Munkvad I.
        Stereotyped activities produced by amphetamine in several animal species and man.
        Psychopharmacologia. 1967; 11: 300-310
        • Fasano A.
        • Barra A.
        • Nicosia P.
        • et al.
        Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding.
        Drug Alcohol Depend. 2008; 96: 178-182
        • Aliane V.
        • Perez S.
        • Bohren Y.
        • et al.
        Key role of striatal cholinergic interneurons in processes leading to arrest of motor stereotypies.
        Brain. 2010; 134: 110-118
        • Pierce R.C.
        • Kalivas P.W.
        A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants.
        Brain Res Brain Res Rev. 1997; 25: 192-216
        • Antonini A.
        • Siri C.
        • Santangelo G.
        • et al.
        Impulsivity and compulsivity in drug-naive patients with Parkinson’s disease.
        Mov Disord. 2011; 26: 464-468
        • Weintraub D.
        • Koester J.
        • Potenza M.N.
        • et al.
        Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
        Arch Neurol. 2010; 67: 589-595
        • Guilarte T.R.
        Is methamphetamine abuse a risk factor in parkinsonism?.
        Neurotoxicology. 2001; 22: 725-731
        • McCann U.D.
        • Kuwabara H.
        • Kumar A.
        • et al.
        Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users.
        Synapse. 2008; 62: 91-100
        • Truong J.G.
        Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
        J Pharmacol Exp Ther. 2005; 314: 1087-1092
        • Volkow N.D.
        • Chang L.
        • Wang G.J.
        • et al.
        Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.
        J Neurosci. 2001; 21: 9414-9418
        • Volkow N.D.
        • Chang L.
        • Wang G.J.
        • et al.
        Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.
        Am J Psychiatry. 2001; 158: 377-382
        • Johanson C.E.
        • Frey K.A.
        • Lundahl L.H.
        • et al.
        Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.
        Psychopharmacology (Berl). 2006; 185: 327-338
        • Boileau I.
        • Rusjan P.
        • Houle S.
        • et al.
        Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?.
        J Neurosci. 2008; 28: 9850-9856
        • Desai R.I.
        • Bergman J.
        Drug discrimination in methamphetamine-trained rats: effects of cholinergic nicotinic compounds.
        J Pharmacol Exp Ther. 2010; 335: 807-816
        • Weinberger A.H.
        • Sofuoglu M.
        The impact of cigarette smoking on stimulant addiction.
        Am J Drug Alcohol Abuse. 2009; 35: 12-17
        • Hernán M.A.
        • Takkouche B.
        • Caamaño-Isorna F.
        • et al.
        A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease.
        Ann Neurol. 2002; 52: 276-284
        • Christine C.W.
        • Garwood E.R.
        • Schrock L.E.
        • et al.
        Parkinsonism in patients with a history of amphetamine exposure.
        Mov Disord. 2010; 25: 228-231
        • Callaghan R.C.
        • Cunningham J.K.
        • Sajeev G.
        • et al.
        Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders.
        Mov Disord. 2010; 25: 2333-2339
        • Garwood E.R.
        • Bekele W.
        • McCulloch C.E.
        • et al.
        Amphetamine exposure is elevated in Parkinson’s disease.
        Neurotoxicology. 2006; 27: 1003-1006
        • Janavs J.L.
        • Aminoff M.J.
        Dystonia and chorea in acquired systemic disorders.
        J Neurol Neurosurg Psychiatry. 1998; 65: 436-445
        • Shanson B.
        Amphetamine poisoning.
        Br Med J. 1956; 1: 576
        • Downes M.A.
        • Whyte I.M.
        Amphetamine-induced movement disorder.
        Emerg Med Australas. 2005; 17: 277-280
        • Mattson R.H.
        • Calverley J.R.
        Dextroamphetamine-sulfate-induced dyskinesias.
        JAMA. 1968; 204: 400-402
        • Morgan J.C.
        • Winter W.C.
        • Wooten G.F.
        Amphetamine-induced chorea in attention deficit-hyperactivity disorder.
        Mov Disord. 2004; 19: 840-842
        • Sperling L.S.
        • Horowitz J.L.
        Methamphetamine-induced choreoathetosis and rhabdomyolysis.
        Ann Intern Med. 1994; 121: 986
        • Klawans H.L.
        • Weiner W.J.
        The effect of d-amphetamine on choreiform movement disorders.
        Neurology. 1974; 24: 312-318
        • Volkow N.D.
        • Chang L.
        • Wang G.J.
        • et al.
        Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex.
        Am J Psychiatry. 2001; 158: 2015-2021
        • Bartzokis G.
        • Beckson M.
        • Wirshing D.A.
        • et al.
        Choreoathetoid movements in cocaine dependence.
        Biol Psychiatry. 1999; 45: 1630-1635
        • Daras M.
        • Koppel B.S.
        • Atos-Radzion E.
        Cocaine-induced choreoathetoid movements (’crack dancing’).
        Neurology. 1994; 44: 751-752
        • Stork C.M.
        • Cantor R.
        Pemoline induced acute choreoathetosis: case report and review of the literature.
        J Toxicol Clin Toxicol. 1997; 35: 105-108
        • Klasser G.D.
        • Epstein J.
        Methamphetamine and its impact on dental care.
        J Can Dent Assoc. 2005; 71: 759-762
        • ADA
        Methamphetamine use and oral health.
        J Am Dent Assoc. 2005; 136: 1491
        • Shaner J.W.
        • Kimmes N.
        • Saini T.
        • et al.
        "Meth mouth": rampant caries in methamphetamine abusers.
        AIDS Patient Care STDS. 2006; 20: 146-150
        • Saini T.
        • Edwards P.C.
        • Kimmes N.S.
        • et al.
        Etiology of xerostomia and dental caries among methamphetamine abusers.
        Oral Health Prev Dent. 2005; 3: 189-195
        • Donaldson M.
        • Goodchild J.H.
        Oral health of the methamphetamine abuser.
        Am J Health Syst Pharm. 2006; 63: 2078-2082
        • Richards J.R.
        • Brofeldt B.T.
        Patterns of tooth wear associated with methamphetamine use.
        J Periodontol. 2000; 71: 1371-1374
        • Morio K.A.
        • Marshall T.A.
        • Qian F.
        • et al.
        Comparing diet, oral hygiene and caries status of adult methamphetamine users and nonusers: a pilot study.
        J Am Dent Assoc. 2008; 139: 171-176
        • Winocur E.
        • Gavish A.
        • Voikovitch M.
        • et al.
        Drugs and bruxism: a critical review.
        J Orofac Pain. 2003; 17: 99-111
        • Winocur E.
        • Gavish A.
        • Volfin G.
        • et al.
        Oral motor parafunctions among heavy drug addicts and their effects on signs and symptoms of temporomandibular disorders.
        J Orofac Pain. 2001; 15: 56-63
        • Di Cugno F.
        • Perec C.J.
        • Tocci A.A.
        Salivary secretion and dental caries experience in drug addicts.
        Arch Oral Biol. 1981; 26: 363-367
        • Shetty V.
        • Mooney L.J.
        • Zigler C.M.
        • et al.
        The relationship between methamphetamine use and increased dental disease.
        J Am Dent Assoc. 2010; 141: 307-318
        • Götrick B.
        • Giglio D.
        • Tobin G.
        Effects of amphetamine on salivary secretion.
        Eur J Oral Sci. 2009; 117: 218-223
        • Kuczenski R.
        • Segal D.S.
        • Cho A.K.
        • et al.
        Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine.
        J Neurosci. 1995; 15: 1308-1317
        • Lobbezoo F.
        • Naeije M.
        Bruxism is mainly regulated centrally, not peripherally.
        J Oral Rehabil. 2001; 28: 1085-1091